메인비쥬얼
Group Introduction
메인 컨텐츠
News
| Title | Huons Meditech Officially Launches ‘Dermashine Duo RF’, Combining Drug Delivery with Radiofrequency | |||
|---|---|---|---|---|
| User | PR | Date | 2025-12-01 | |
| Attachment | ||||
|
Huons Meditech Officially Launches ‘Dermashine Duo RF’, Combining Drug Delivery with Radiofrequency - A variety of aesthetic treatments possible with a single device -
Huons Meditech’s electrically powered drug delivery device ‘Dermashine Duo RF’
Huons Meditech, a medical device subsidiary of Huons Group, has introduced a new ‘Dermashine’ device that enables a variety of facial aesthetic treatments using one device, aiming to expand its market base. Huons Meditech (CEO Changwoo Ha) announced on December 1st that it has launched ‘Dermashine Duo RF’, a new device that combines precise drug delivery with radiofrequency (RF) technology. Newly launched ‘Dermashine Duo RF’ is a hybrid medical device that integrates electrically powered drug delivery function of the existing Dermashine devices with low-output radiofrequency (RF) energy delivery. The heat generated during RF treatment coagulates tissue and stimulates collagen regeneration, creating synergistic effects such as improved skin firmness, reduced pore size, and softening of fine lines. Using a single platform, physicians can sequentially perform both drug delivery and RF lifting, reducing treatment time and the number of sessions compared with performing the two procedures separately, while enhancing overall patient satisfaction. ‘Dermashine Duo RF’ is compatible with a range of needle tips, including 31G, 32G, and 34G, allowing the device to support various injection needs. It is optimized for the delivery of high-viscosity polymer skin boosters such as poly-L-lactic acid (PLLA), poly-D-lactic acid (PDLA), and polycaprolactone (PCL). By incorporating an enhanced pressure-sensing automatic injection system, the device helps reduce pain and provides a safer, more comfortable treatment experience, while also minimizing drug loss during the injection process. CEO Changwoo Ha stated, “There is a strong trend toward aesthetic treatment that deliver combined, synergistic effects rather than single effects. Dermashine Duo RF has been developed to pair its core value of precise drug delivery with RF technology that maximizes treatment outcomes, and is expected to introduce a new paradigm in aesthetic treatments.” ‘Dermashine’ is Huons Meditech’s aesthetic medical device brand with over 20,000 units sold worldwide since its initial launch in 2011. By closely bringing together the gap between the needles and the skin surface, Dermashine ensures to deliver therapeutic solutions evenly into the dermal layer of the skin, thereby directly improving skin condition. |
||||
| Number | Title | Date | Read |
|---|---|---|---|
| 92 | Huons Global Reports FY2025 Results, Revenue of KRW 847.5 Billion.. | 2026-02-13 | 88 |
| 91 | Huonslab on Track for Recombinant Human Hyaluronidase ‘HYDIZYME.. | 2026-02-11 | 116 |
| 90 | Huons Meditech Showcases at ‘WHX Dubai 2026’, Accelerating Ex.. | 2026-02-10 | 102 |
| 89 | PanGen Biotech Announces FY2025 Results, Revenue of KRW 13.42 Bil.. | 2026-02-03 | 151 |
| 88 | Huons Signs Distribution Agreement with Rappeler for Vitamin C an.. | 2026-01-30 | 203 |
| 87 | Humedix Celebrated a Symposium to Mark the Launch of Three Types .. | 2026-01-22 | 346 |
| 86 | Humedix Announces Syrian Approval for Three Types of HA Filler .. | 2026-01-12 | 379 |
| 85 | Huons BioPharma Secures NMPA Approval for Type A Botulinum Toxin .. | 2026-01-09 | 537 |
| 84 | Huons Group Kicks Off New Year with Employees, “New Beginning f.. | 2026-01-06 | 358 |
| 83 | Huonslab has submitted the Biologics License Application for Reco.. | 2025-12-22 | 731 |


